Actively Recruiting
Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis
Led by Telios Pharma, Inc. · Updated on 2024-11-13
66
Participants Needed
1
Research Sites
9 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
In this prospective, Phase 2, randomized, double-masked, vehicle controlled study, approximately 66 eligible subjects will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally. The study comprises of a screening and treatment period using the conjunctival allergen challenge model to evaluate TL-925 for the treatment of allergic conjunctivitis.
CONDITIONS
Official Title
Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Individuals aged 18 years or older
- Female subjects of childbearing potential and their male partners must both use a highly effective contraception method during the study
- Documented history of ocular allergies and a positive skin test to seasonal or perennial allergens within the past 60 months
- Best-corrected visual acuity of 0.7 LogMAR or better
- Positive bilateral conjunctival allergen challenge reaction
You will not qualify if you...
- Any systemic or ocular disease causing eye redness or discomfort or interfering with the study
- Any eye surgery within the last 3 months or refractive surgery within the last 6 months
- Any ongoing ocular infection (bacterial, viral, or fungal)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Telios Investigative Site
Memphis, Tennessee, United States, 38119
Actively Recruiting
Research Team
J
John Mei
CONTACT
Y
Yulia Khalina
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here